立体定向放疗后帕博利珠单抗对比单药治疗晚期NSCLC的II期随机试验
PEMBRO-RT多中心II期随机试验纳入92例晚期NSCLC患者,比较帕博利珠单抗单药与单部位立体定向放疗后帕博利珠单抗的疗效。PD-L1阴性亚组从放疗联合中获益最大,且未增加毒性。
要点
- PD-L1阴性亚组接受放疗联合后PFS和OS显著改善。
- 联合治疗未增加治疗相关毒性。
核心结论
- 帕博利珠单抗前给予单部位立体定向放疗耐受性良好,ORR翻倍但未达到预设的临床获益终点。
- 阳性结果主要由PD-L1阴性亚组驱动,该亚组PFS和OS显著改善。
- 需更大规模试验验证放疗能否将非炎症型NSCLC转化为更炎症型的肿瘤微环境。
研究设计与样本
- 多中心、随机II期研究(PEMBRO-RT),2015年7月1日至2018年3月31日入组92例晚期NSCLC患者,不限PD-L1状态。
- 意向性治疗人群分析,76例随机分为对照组(n=40)和实验组(n=36)。
- 干预为帕博利珠单抗单药或单部位放疗(3次8 Gy)后帕博利珠单抗,直至确认影像学进展、不可接受毒性、研究者决定、患者撤回同意或最长24个月。
主要发现
- 亚组分析显示PD-L1阴性肿瘤患者从联合放疗中获益最大,且实验组未增加治疗相关毒性。
临床怎么用
- 对于晚期NSCLC,单部位SBRT后帕博利珠单抗方案耐受性良好,但整体人群未显示显著ORR获益。
- PD-L1阴性患者可能从放疗联合免疫治疗中获得PFS和OS改善,但需更大规模试验确认。
- 不推荐在缺乏进一步证据的情况下常规临床使用该联合方案。
局限性
- 样本量较小(92例入组,76例随机),统计效能有限。
- 主要终点未达到预设的临床获益标准。
- 亚组分析结果需谨慎解读,可能存在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Many patients with advanced non-small cell lung cancer (NSCLC) receiving immunotherapy show primary resistance. High-dose radiotherapy can lead to increased tumor antigen release, improved antigen presentation, and T-cell infiltration. This radiotherapy may enhance the effects of checkpoint inhibition. OBJECTIVE: To assess whether stereotactic body radiotherapy on a single tumor site preceding pembrolizumab treatment enhances tumor response in patients with metastatic NSCLC. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized phase 2 study (PEMBRO-RT) of 92 patients with advanced NSCLC enrolled between July 1, 2015, and March 31, 2018, regardless of programmed death-ligand 1 (PD-L1) status. Data analysis was of the intention-to-treat population. INTERVENTIONS: Pembrolizumab (200 mg/kg every 3 weeks) either alone (control arm) or after radiotherapy (3 doses of 8 Gy) (experimental arm) to a single tumor site until confirmed radiographic progression, unacceptable toxic effects, investigator decision, patient withdrawal of consent, or a maximum of 24 months. MAIN OUTCOMES AND MEASURES: Improvement in overall response rate (ORR) at 12 weeks from 20% in the control arm to 50% in the experimental arm with P < .10. RESULTS: Of the 92 patients enrolled, 76 were randomized to the control arm (n = 40) or the experimental arm (n = 36). Of those, the median age was 62 years (range, 35-78 years), and 44 (58%) were men. The ORR at 12 weeks was 18% in the control arm vs 36% in the experimental arm (P = .07). Median progression-free survival was 1.9 months (95% CI, 1.7-6.9 months) vs 6.6 months (95% CI, 4.0-14.6 months) (hazard ratio, 0.71; 95% CI, 0.42-1.18; P = .19), and median overall survival was 7.6 months (95% CI, 6.0-13.9 months) vs 15.9 months (95% CI, 7.1 months to not reached) (hazard ratio, 0.66; 95% CI, 0.37-1.18; P = .16). Subgroup analyses showed the largest benefit from the addition of radiotherapy in patients with PD-L1-negative tumors. No increase in treatment-related toxic effects was observed in the experimental arm. CONCLUSIONS AND RELEVANCE: Stereotactic body radiotherapy prior to pembrolizumab was well tolerated. Although a doubling of ORR was observed, the results did not meet the study's prespecified end point criteria for meaningful clinical benefit. Positive results were largely influenced by the PD-L1-negative subgroup, which had significantly improved progression-free survival and overall survival. These results suggest that a larger trial is necessary to determine whether radiotherapy may activate noninflamed NSCLC toward a more inflamed tumor microenvironment. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02492568.
引用
- Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 31294749. doi:10.1001/jamaoncol.2019.1478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。